EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation.

P. Seizer,T. Schönberger,Moritz Schött,M. Lang,H. Langer,B. Bigalke,Björn F. Krämer,O. Borst,K. Daub,O. Heidenreich,R. Schmidt,S. Lindemann,Y. Herouy,M. Gawaz,A. May

DOI: https://doi.org/10.1016/j.atherosclerosis.2009.08.029

IF: 5.3

2010-03-01

Atherosclerosis

Abstract:

What problem does this paper attempt to address?

Small Intestinal Bacterial Overgrowth in Patients with Irritable Bowel Syndrome: Clinical Characteristics, Psychological Factors, and Peripheral Cytokines

Hua Chu,Mark Fox,Xia Zheng,Yanyong Deng,Yanqin Long,Zhihui Huang,Lijun Du,Fei Xu,Ning Dai

DOI: https://doi.org/10.1155/2016/3230859

IF: 2

2016-01-01

Gastroenterology Research and Practice

Abstract:Small intestinal bacterial overgrowth (SIBO) has been implicated in the pathogenesis of irritable bowel syndrome (IBS). Psychosocial factors and low-grade colonic mucosal immune activation have been suggested to play important roles in the pathophysiology of IBS. In total, 94 patients with IBS and 13 healthy volunteers underwent a 10 g lactulose hydrogen breath test (HBT) with concurrent Tc99m scintigraphy. All participants also completed a face-to-face questionnaire survey, including the Hospital Anxiety and Depression Scale, Life Event Stress (LES), and general information. Serum tumour necrosis factor-α, interleukin- (IL-) 6, IL-8, and IL-10 levels were measured. The 89 enrolled patients with IBS and 13 healthy controls had no differences in baseline characteristics. The prevalence of SIBO in patients with IBS was higher than that in healthy controls (39% versus 8%, resp.; p=0.026). Patients with IBS had higher anxiety, depression, and LES scores, but anxiety, depression, and LES scores were similar between the SIBO-positive and SIBO-negative groups. Psychological disorders were not associated with SIBO in patients with IBS. The serum IL-10 level was significantly lower in SIBO-positive than SIBO-negative patients with IBS.
Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis

Binrui Chen,John Jae-Woo Kim,Yawen Zhang,Lijun Du,Ning Dai

DOI: https://doi.org/10.1007/s00535-018-1476-9

2018-01-01

Journal of Gastroenterology

Abstract:Background The reported prevalence of small intestinal bacterial overgrowth (SIBO) among individuals with irritable bowel syndrome (IBS) is highly variable. The aim of the study is to estimate the prevalence and identify predictors of SIBO in IBS. Methods PubMed, Cochrane Library, and EMBASE through July 2017 were searched to identify studies evaluating the prevalence of SIBO in IBS. The pooled prevalence of SIBO among individuals with IBS and the pooled odds ratio (OR) of SIBO among those with IBS compared with healthy controls were calculated. Predictors of SIBO among IBS patients were also evaluated. Results Fifty studies (8398 IBS, 1432 controls) met the inclusion criteria. Overall pooled prevalence of SIBO in IBS was 38% (95% CI 32–44) and was higher among individuals with IBS (OR 4.7, 95% CI 3.1–7.2) compared with controls. The pooled prevalence of SIBO in IBS was higher in studies diagnosed by breath tests (40%, 95% CI 33–46) compared with cultures (19%, 95% CI 8–30). Among those with IBS, female gender (OR 1.5, 95% CI 1.0–2.1), older age (standard mean difference 3.1 years, 95% CI 0.9–5.4), and IBS-diarrhea (OR 1.7, 95% CI 1.3–2.3) compared with other IBS subtypes increased the odds of SIBO; proton pump inhibitor (PPI) use (OR 1.1, 95% CI 0.7–1.7) was not associated with SIBO. Conclusions More than one-third of IBS patients tested positive for SIBO, and the odds of SIBO in IBS were increased by nearly fivefold. The prevalence of SIBO varied according to the diagnostic modality performed. Female gender, older age, and IBS-diarrhea, but not PPI use, were associated with SIBO among individuals with IBS.
Clinical Value of Radionuclide Small Intestine Transit Time Measurement Combined with Lactulose Hydrogen Breath Test for the Diagnosis of Bacterial Overgrowth in Irritable Bowel Syndrome.

Yanli Ning,Cen Lou,Zhongke Huang,Dongfang Chen,Huacheng Huang,Liang Chen,Bucheng Zhang,Ning Dai,Jianmin Zhao,Xia Zhen

DOI: https://doi.org/10.1967/s002449910365

2016-01-01

Abstract:OBJECTIVE:Small intestine bacterial overgrowth (SIBO) may be a pathogenetic factor for irritable bowel syndrome (IBS). This syndrome cannot be explained by structural abnormalities and has no specific diagnostic laboratory tests or biomarkers. We studied quantitatively and semi-quantitatively, using lactulose hydrogen breath test (LHBT), small intestinal transit time (SITT) (99m)technetium-diethylene triamine pentaacetic acid ((99m)Tc-DTPA) in order to examine the mobility of small intestine as an indication of bacterial overgrowth in patients.METHODS:Eighty nine consecutive patients who met Rome criteria for IBS were retrospectively studied. According to the diagnostic criteria, all patients were divided into two groups: the SIBO group and the non-SIBO group. The tracer was a mixture of 10g lactulose, 37MBq (99m)Tc-DTPA and 100mL water. The patient drank the whole mixture during 1min and the SITT study started immediately. The SITT and the LHBT followed every 15min for up to 3h after emptying the urine bladder. Spearman's rank correlation was applied to assess the correlation of oro-cecum transit time (OCTT) between imaging and LHBT. The semi-quantitative index between the SIBO group and the non-SIBO group was analyzed with Wilcoxon's rank sum test. If there was significant group difference, the receiver operating characteristic (ROC) curve was used. P<0.05 was considered significant.RESULTS:The median and inter-quartile range for OCTT for the LHBT (OCTT-L) for all patients was 90min and 60min, respectively, and 75min and 45min for OCTT for the SITT study (OCTT-i). There was positive correlation between OCTT-L and OCTT-i at the 0.05 level (R=0.290, P=0.000). There were no differences in OCTT-i and in the rate of radioactivity (counts of regions of interest ROI) over the abdomen between the SIBO group and the non-SIBO group (P=0.116 and 0.290). There were significant differences in the temporal association of the hydrogen (H2) value with OCTT-i (H2-i) and OCTT-L between the two groups (P=0.000 and 0.000). The areas under the curve (AUC) of H2-i and OCTT-L were 0.749 and 0.138 respectively.CONCLUSION:Small intestinal transit time study using a lactose hydrogen breath test and (99m)Tc-DTPA is a real-time test for small intestine bacteria overgrowth in IBS patients and can be used as an indicator of the disease.
A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients.

J Zhao,X Zheng,H Chu,J Zhao,Y Cong,M Fried,M Fox,N Dai

DOI: https://doi.org/10.1111/nmo.12331

2014-01-01

Abstract:BACKGROUND:Small intestinal bacterial overgrowth (SIBO) may be a cause of irritable bowel syndrome (IBS); however, current investigations have important limitations. We aimed to identify clinically relevant diagnostic criteria for SIBO based on lactulose hydrogen breath test (LHBT) alone and combined with scintigraphic measurement of oro-cecal transit (SOCT). METHODS:Results of LHBT/SOCT investigation from 89 IBS patients and 13 healthy volunteers were included in a systematic analysis of six published criteria for SIBO diagnosis. Clinical relevance of competing criteria was determined by assessing (i) prevalence of SIBO in IBS patients and healthy volunteers (ii) if SIBO diagnosis predicted improvement in IBS symptoms in a prospective, pilot therapeutic trial of a non-absorbable antibiotic (rifaximin 600 mg b.d.) in IBS patients. KEY RESULTS:Reproducibility of SIBO diagnosis by combined LHBT/SOCT was near perfect. A ≥5 ppm H2 increase prior to appearance of cecal contrast was detected in more IBS patients than healthy volunteers (35/89 vs 1/13; p = 0.026), but not for other diagnostic criteria. IBS patients with SIBO, compared to those without SIBO, reported significantly greater improvement in abdominal symptoms following rifaximin therapy (p < 0.002 overall IBS symptom severity). This improvement was most marked in D-IBS patients in whom all symptoms improved, including stool frequency and consistency (all p < 0.004). CONCLUSIONS & INFERENCES:Combined LHBT/SOCT testing using a H2 5 ppm cutoff may identify a subgroup of IBS patients with SIBO. Pilot data examining the clinical response to rifaximin suggest that this subset of IBS patients may benefit more than those with a normal test.
Lactose intolerance in patients with chronic functional diarrhoea: the role of small intestinal bacterial overgrowth.

J Zhao,M Fox,Y Cong,H Chu,Y Shang,M Fried,N Dai

DOI: https://doi.org/10.1111/j.1365-2036.2010.04252.x

IF: 9.524

2010-01-01

Alimentary Pharmacology & Therapeutics

Abstract:P>Background Many studies report a high prevalence of lactose intolerance in patients with functional, gastrointestinal disease. Aim To evaluate the role of small intestinal bacterial overgrowth (SIBO) in condition of lactose intolerance and the mechanism by which SIBO may impact lactose tolerance in affected patients. Methods Consecutive out-patients with chronic functional diarrhoea (CFD) and healthy controls underwent a validated 20 g lactose hydrogen breath test (HBT). Patients completed also a 10 g lactulose HBT with concurrent assessment of small bowel transit by scintigraphy. Results Lactose malabsorption was present in 27/31 (87%) patients with CFD and 29/32 (91%) healthy controls (P = 0.708). From the patient group 14/27 (52%) had lactose intolerance and 13/27 (48%) experienced no symptoms (lactose malabsorption controls). Only 5 (17%) healthy controls reported symptoms (P < 0.01). The oro-caecal transit time was similar between patient groups with or without symptoms (P = 0.969). SIBO was present in 11 (41%) subjects and was more prevalent in lactose intolerance than in lactose malabsorption [9/14 (64%) vs. 2/13 (15%), P = 0.018]. Symptom severity was similar in lactose intolerance patients with and without SIBO (P = 0.344). Conclusions Small intestinal bacterial overgrowth increases the likelihood of lactose intolerance in patients with CFD as a direct result of lactose fermentation in the small intestine, independent of oro-caecal transit time and visceral sensitivity.
Prevalence and presentation of lactose intolerance and effects on dairy product intake in healthy subjects and patients with irritable bowel syndrome.

Jianfeng Yang,Yanyong Deng,Hua Chu,Yanqun Cong,Jianmin Zhao,Daniel Pohl,Benjamin Misselwitz,Michael Fried,Ning Dai,Mark Fox

DOI: https://doi.org/10.1016/j.cgh.2012.11.034

IF: 13.576

2013-01-01

Clinical Gastroenterology and Hepatology

Abstract:The effects of lactase deficiency on digestive symptoms and diet in patients with irritable bowel syndrome (IBS) have not been well defined. We assessed lactose absorption and tolerance and the intake of dairy products in healthy volunteers (controls) and patients with diarrhea-predominant IBS (D-IBS).Sixty patients diagnosed with D-IBS at the Sir Run Run Shaw Hospital, Hangzhou, China and 60 controls were given hydrogen breath tests to detect malabsorption and intolerance after administration of 10, 20, and 40 g lactose in random order 7-14 days apart; participants and researchers were blinded to the dose. We assessed associations between the results and self-reported lactose intolerance (LI).Malabsorption of 40 g lactose was observed in 93% of controls and 92% of patients with D-IBS. Fewer controls than patients with D-IBS were intolerant to 10 g lactose (3% vs 18%; odds ratio [OR], 6.51; 95% confidence interval [CI], 1.38-30.8; P = .008), 20 g lactose (22% vs 47%; OR, 3.16; 95% CI, 1.43-7.02; P = .004), and 40 g lactose (68% vs 85%; OR, 2.63; 95% CI, 1.08-6.42; P = .03). H(2) excretion was associated with symptom score (P = .001). Patients with D-IBS self-reported LI more frequently than controls (63% vs 22%; OR, 6.25; 95% CI, 2.78-14.0; P < .001) and ate fewer dairy products (P = .040). However, self-reported LI did not correlate with results from hydrogen breath tests.The risk of LI is related to the dose of lactose ingested and intestinal gas production and is increased in patients with D-IBS. Self-reported LI, but not objective results from hydrogen breath tests, was associated with avoidance of dairy products.
Prevalence of small intestinal bacterial overgrowth syndrome among patients with inflammatory bowel disease and its impact on nutritional status and clinical manifestations

Yu.M. Stepanov,M.V. Titova,N.V. Nedzvetska

DOI: https://doi.org/10.22141/2308-2097.55.3.2021.241586

IF: 29.4

2022-01-04

Gastroenterology

Abstract:Background. In recent years, there has been high interest in the prevalence of small intestinal bacterial overgrowth (SIBO) syndrome in various populations. Chronic inflammatory bowel disease (IBD) is known to be a heterogeneous group of disorders, with a high degree of geographical variability in terms of symptoms, nature of progression, clinical manifestations, or combination with other types of pathologies. Since the involvement of the intestinal microbiome plays an important role in the etiopathogenesis of inflammatory bowel disease, the combination of SIBO and IBD is increasingly being considered and studied recently. Since the symptoms of both pathological conditions are significantly echoed, and therefore exacerbated by the combination, the manifestations of malnutrition become more pronounced, which negatively affects the nutritional status of patients with IBD. The purpose of the study is to determine the frequency of SIBO in patients with IBD depending on the nosological forms and to investigate its effect on clinical and laboratory indicators of nutritional status and clinical manifestations. Materials and methods. We examined 100 patients with IBD, aged 19 to 79 years, on average (42.54 ± 1.50) years, including 70 patients with ulcerative colitis (UC), and 30 — with Crohn’s disease (CD). All patients underwent general clinical examination, anthropometric measurements, general and biochemical blood tests (with the determination of total protein, albumin, prealbumin). To characterize the state of the small intestine microbiota (presence of SIBO), all patients underwent a hydrogen breath test with glucose loading using a Gastro+ Gastrolyzer gas analyzer from Bedfont Scientific Ltd (UK). Results. The analysis of SIBO frequency showed the changes in the state of the small intestinal microflora in 45 % of patients with IBD. The prevalence of SIBO was higher in the group of patients with CD — 53.3 % (16) than in the group with UC — 41.4 % (29). The presence of SIBO in the group of patients with UC had statistical significance and a direct correlation with the duration of the disease — (9.3 ± 6.2) versus (2.9 ± 3.1) years (p = 0.001, r = 0.55). There was a decrease in weight and body mass index (BMI) in patients with SIBO, especially in patients with Crohn’s disease, and accounted for (19.8 ± 3.5) kg/m2. There was a significant difference between the levels of total protein in patients with SIBO and without it, both in the basic group and in the group of UC: (65.8 ± 8.4) vs. (70.2 ± 8.2) g/l (p = 0.009, r = –0.232) and (66.5 ± 8.3) vs. (70.7 ± 7.4) g/l (p = 0.029), respectively, and albumin levels were reduced in both nosological groups. No relationship was found between the severity of abdominal pain and the presence of SIBO. When SIBO was detected, the manifestations of flatulence significantly prevailed in patients with UC — 75.8 % (n = 22), and diarrheal syndrome in patients with CD — 75 % (n = 12). Conclusions. The obtained results indicate a high prevalence of SIBO in patients with IBD. Patients with CD suffered from SIBO more often (53.3 %) than patients with UC (41.4 %) (with a predominance of patients with severe disease). A direct correlation of SIBO with the disease duration in patients with UC (r = 0.55, р < 0.05) was revealed, which is explained by the violation of physiological barriers that prevent the emergence of SIBO, due to more episodes of exacerbation, long-term use of drugs and concomitant pathology with time. The negative impact of SIBO on nutritional status manifested in weight loss, reduced BMI and other anthropometric (mid-upper arm circumference, mid-arm muscle circumference, triceps skinfold) and laboratory (total protein, albumin, prealbumin) parameters in these patients. The most common symptoms in patients with IBD with SIBO were abdominal pain, diarrhea, and flatulence that reflected the typical clinical picture of SIBO.

gastroenterology & hepatology
Advances in Study on the Pathogenesis and Diagnosis of Small Intestinal Bacterial Overgrowth

ZHENG Xia,DAI Ning

DOI: https://doi.org/10.3969/j.issn.1008-7125.2012.08.013

2012-01-01

Abstract:Small intestinal bacterial overgrowth(SIBO) has a close association with gastrointestinal diseases and the pathogenesis is quite complicated.Although various techniques are available to make the diagnosis of SIBO,bacterial culture of small intestinal aspirate has been accepted as a golden standard,however,it's difficult to promote in clinical application because of the invasiveness and complexity in procedure.In the diagnosis of SIBO,various breath tests are widely used because of simple,non-invasive and convenience in operation,however,the sensitivity and specificity are frequently influenced by many factors.Therefore,searching for a simple and accurate diagnostic method has been an urgent task.This article reviewed the advances in study on the pathogenesis and diagnosis of SIBO.
Dietary Challenge Tests: Identifying Food Intolerance As a Cause of Symptoms in Irritable Bowel Syndrome Patients.

Yanyong Deng,Yujin Zhu,Ning Dai

DOI: https://doi.org/10.1016/j.cgh.2016.04.011

IF: 13.576

2016-01-01

Clinical Gastroenterology and Hepatology

Abstract:We have read with interest the recent study by Le Nevé et al1Le Neve B. et al.Clin Gastroenterol Hepatol. 2016; 14: 226-233 e3Abstract Full Text Full Text PDF Scopus (34) Google Scholar that assessed visceral sensitivity and symptom severity in patients with irritable bowel syndrome (IBS) following a combined nutrient and lactulose challenge. The authors report that symptom severity assessed by validated questionnaires was significantly higher in patients with “high-intensity gastrointestinal (GI) symptoms” compared with those with “low-intensity GI symptoms” after the test meal. The high-intensity GI symptoms group also had high levels of anxiety and elevated Visceral Sensitivity Index scores (both P < .05). Furthermore, compared with the low-intensity GI symptoms group, patients in the high-intensity GI symptoms group had higher rectal sensitivity to phasic distentions administered by an electronic barostat (P < .05–.001). It is well known that patients with functional GI disorders are more likely to report food intolerance than healthy individuals.2Bohn L. et al.Am J Gastroenterol. 2013; 108: 634-641Google Scholar, 3Zheng X. et al.Neurogastroenterol Motil. 2015; 27: 1138-1146Google Scholar Indeed, the striking similarity between IBS and food intolerance symptoms suggests that malabsorption of certain foods (eg, fermentable oligosaccharides, disaccharides, monosaccharides, and polyols [FODMAP]) is an important cause of abdominal symptoms in many patients with IBS.4Shepherd S.J. et al.Clin Gastroenterol Hepatol. 2008; 6: 765-771Google Scholar, 5Halmos E.P. et al.Gastroenterology. 2014; 146: 67-75 e5Google Scholar Chemically similar to lactulose, lactose is a disaccharide FODMAP in patients with lactase deficiency. China is a country with a >95% prevalence of primary, genetic lactase deficiency6Yang J. et al.Clin Gastroenterol Hepatol. 2013; 11: 262-268 e1Google Scholar that has seen a large increase in milk consumption in recent years. This combination of genetic susceptibility and environmental challenge may have contributed to the increasing incidence of IBS documented in this population. The lactose hydrogen breath test is a simple, noninvasive investigation for the assessment of lactose absorption and tolerance. Our work in the Chinese population has shown that ingestion of 40-g lactose leads to lactose intolerance in health and disease; however, at the relatively low 20-g lactose dose, symptoms were more than 3 times more common in patients with IBS than in healthy control subjects.6Yang J. et al.Clin Gastroenterol Hepatol. 2013; 11: 262-268 e1Google Scholar In subsequent studies we applied the 20-g lactose hydrogen breath test as a clinical experimental model to identify the factors that determine the increased risk of bloating and functional GI symptoms after lactose ingestion in patients with IBS.6Yang J. et al.Clin Gastroenterol Hepatol. 2013; 11: 262-268 e1Google Scholar, 7Yang J. et al.Aliment Pharmacol Ther. 2014; 39: 302-311Google Scholar, 8Zhu Y. et al.Am J Gastroenterol. 2013; 108: 1516-1525Google Scholar Consistent with findings for the combined nutrient and lactulose challenge,1Le Neve B. et al.Clin Gastroenterol Hepatol. 2016; 14: 226-233 e3Abstract Full Text Full Text PDF Scopus (34) Google Scholar a large case-control study by Zhu et al8Zhu Y. et al.Am J Gastroenterol. 2013; 108: 1516-1525Google Scholar found that the presence of visceral hypersensitivity on rectal barostat studies increased the risk of bloating (odds ratio, 6.61; P = .005) and overall abdominal symptoms (odds ratio, 3.78; P = .014) after ingestion of 20-g lactose. Additionally, the onset of symptoms was closely related to the timing of gas production and high levels of gas production increased the risk of abdominal symptoms (odds ratio, 2.19; P = .028). The fact that Le Nevé et al1Le Neve B. et al.Clin Gastroenterol Hepatol. 2016; 14: 226-233 e3Abstract Full Text Full Text PDF Scopus (34) Google Scholar did not detect the latter effect may be caused by the larger number of subjects in the Chinese study (277 vs 100 patients with IBS). Also previous exposure to dairy products in the Chinese population may have promoted bacteria that metabolize lactose, whereas lactulose is not part of a normal diet (ie, increased sensitivity of H2 breath testing). Together these findings are consistent with the principle that both the size of the stimulus (eg, gas distention) and sensitivity to the stimulus contribute to symptom generation after FODMAP intake. The consistent finding of visceral hypersensitivity in patients with IBS with food intolerance emphasizes the importance of this pathology in functional GI disease.1Le Neve B. et al.Clin Gastroenterol Hepatol. 2016; 14: 226-233 e3Abstract Full Text Full Text PDF Scopus (34) Google Scholar, 7Yang J. et al.Aliment Pharmacol Ther. 2014; 39: 302-311Google Scholar, 8Zhu Y. et al.Am J Gastroenterol. 2013; 108: 1516-1525Google Scholar Looking ahead, FODMAP challenge tests may help to identify the causes of IBS symptoms and to direct more specific and effective therapy. Lactulose Challenge Determines Visceral Sensitivity and Severity of Symptoms in Patients With Irritable Bowel SyndromeClinical Gastroenterology and HepatologyVol. 14Issue 2PreviewPatients with irritable bowel syndrome (IBS) can be assigned to groups with different gastrointestinal (GI) symptoms based on results from a combined nutrient and lactulose challenge. We aimed to identify factors that predict outcomes to this challenge and to determine whether this can be used in noninvasive assessment of visceral sensitivity in patients with IBS. Full-Text PDF
Tu2066 Prevalence of Irritable Bowel Syndrome in China: Joint Effects of Psychiatric Morbidity with Life Event Stress and Lactose Intake

Yanqin Long,Yanyong Deng,Hua Chu,Jianfeng Yang,Yubin Zhu,Xia Zheng,Huiqin He,Zhihui Huang,Liang Luo,Michael Fried,Ning Dai,Mark R. Fox

DOI: https://doi.org/10.1016/s0016-5085(13)63422-8

IF: 29.4

2013-01-01

Gastroenterology

Abstract:Background: IBS and IBD are chronic gastrointestinal (GI) conditions associated with abdominal pain and abnormal bowel habits.Although IBS and IBD share common symptoms, their pathogenesis differs.Whereas IBD symptoms often arise from inflammatory or structural abnormalities, these objective markers are not consistently identified in IBS.Because symptom pathogenesis differs between disorders, we aimed to test whether symptom severity also varies between IBS and IBD.Methods: We compared GI symptoms using items developed for the NIH Patient Reported Outcome Measurement Information System (PROMIS®) that assessed frequency, severity, interference, and bother to 3 groups: (1) IBS patients from clinic and community populations, (2) IBD clinic patients, and (3) a U.S. general population (GP) sample selected by a commercial research firm (Cint) to approximate characteristics in the 2010 census.We measured 8 GI symptom domains: gastroesophageal reflux (GERD), disrupted swallowing, nausea/vomiting (N/V), belly pain, diarrhea, constipation, gas/bloating, and fecal incontinence/soling (FI).We measured overall symptom severity by averaging responses to items and transforming linearly to a 0-100 possible range (higher=worse).We compared group differences using analysis of covariance controlling for demographics and GI symptom-specific anxiety (Visceral Sensitivity Index [VSI]).To adjust for multiple comparisons for different symptoms, a p ,0.01 was used.Results: Respondents included 231 with IBS (mean age=44.8yrs; 68%F; 56.3% Caucasian), 190 with IBD (mean age=41.3yrs; 46%F; 58.4% Caucasian) and 1117 from the GP (mean age 45.7; 57%F; 72.7% Caucasian).Mean age, race/ethnicity, and education significantly differed between groups (all p ,0.01).The Table shows differences in GI symptom severity scores between groups.The GP had greater severity of GERD, disrupted swallowing and N/V compared to the patient groups.GERD severity differed among all groups with greatest severity in GP, followed by IBS, and then IBD.GP reported more disrupted swallowing than IBS and greater N/V than IBD.IBS patients reported greater severity of belly pain vs. GP and greater severity of constipation and gas/ bloating vs. GP and IBD.IBD patients had more severe diarrhea than the GP but not IBS.Conclusions: While IBS and IBD are conditions associated with greater lower GI symptom severity compared to the GP, they report less severe upper GI symptoms.Between disease states, IBS patients report numerically worse symptom severity vs. IBD for 7 of 8 GI symptom domains -only diarrhea appeared more severe in IBD.Although IBD is marked by objective inflammatory and anatomic biomarkers, this does not necessarily yield worse symptom severity than IBS -a condition without reliable biomarkers; the converse is true in this study.* P values after controlling for demographics and VSI.Values shown in bold are statistically significant.
Hydrogen Breath Testing with Measurement of Orocecal Transit for Diagnosis of Small Bowel Bacterial Overgrowth.

Yanyong Deng,Ning Dai,Mark Fox

DOI: https://doi.org/10.1016/j.cgh.2016.04.016

2016-01-01

Abstract:We read with interest the study by Lin et al1Lin E.C. et al.Clin Gastroenterol Hepatol. 2016; 14: 203-208Abstract Full Text Full Text PDF PubMed Scopus (58) Google Scholar that reported a high rate of false-positive diagnoses of small bowel bacterial overgrowth (SBBO) by glucose hydrogen breath testing (HBT) with nearly 50% of diagnoses being false-positives caused by rapid transit and early colonic fermentation of unabsorbed substrate. This effect was most marked in patients with previous upper gastrointestinal surgery (65% vs 13% in patients without prior surgery). Lactulose is a poorly absorbed, fermentable disaccharide that has also been used to detect SBBO by HBT. The lactulose HBT is said to be more sensitive than glucose HBT or bacterial culture of jejunal aspirates (the “reference standard”) because it can detect cases with distal SBBO and pathologic bacterial strains that do not culture well.2Schiller L.R. Curr Gastroenterol Rep. 2007; 9: 373-377Crossref PubMed Scopus (32) Google Scholar Unfortunately, clinical studies have also shown that lactulose HBT does not provide a reliable diagnosis of SBBO because of variability in orocecal transit time.1Lin E.C. et al.Clin Gastroenterol Hepatol. 2016; 14: 203-208Abstract Full Text Full Text PDF PubMed Scopus (58) Google Scholar, 3Corazza G.R. et al.Gastroenterology. 1990; 98: 302-309Abstract Full Text PDF PubMed Google Scholar, 4Yu D. et al.Gut. 2011; 60: 334-340Crossref PubMed Scopus (202) Google Scholar To address this limitation, investigators have combined lactulose HBT with concurrent scintigraphic assessment of orocecal transit. The diagnosis of SBBO is confirmed if there is a physiologically relevant increase in breath hydrogen well before labeled substrate enters the caecum. Using this approach, Zhao et al5Zhao J. et al.Aliment Pharmacol Ther. 2010; 31: 892-900PubMed Google Scholar found that the combined test identified SBBO in at least 1 in 3 patients with irritable bowel syndrome (IBS) and also that the presence of bacteria in the small bowel was associated with increased risk of lactose intolerance in a population with lactase deficiency. Consistent with the findings of Lin et al,1Lin E.C. et al.Clin Gastroenterol Hepatol. 2016; 14: 203-208Abstract Full Text Full Text PDF PubMed Scopus (58) Google Scholar the orocecal transit time was similar in those with and without SBBO (63 min vs 56 min; P = .071).5Zhao J. et al.Aliment Pharmacol Ther. 2010; 31: 892-900PubMed Google Scholar Moreover there was no difference in orocecal transit time between patients with IBS and healthy control subjects (74 min vs 68 min; P = .433).5Zhao J. et al.Aliment Pharmacol Ther. 2010; 31: 892-900PubMed Google Scholar Thus, it was only the presence of abnormal findings on combined lactulose HBT and scinitigraphy that identified possible SIBO in the patients with IBS. Subsequently, a prospective study by the same group demonstrated that the results of the combined test can also guide therapy. Beneficial effects of antibiotic treatment (rifaximin) on IBS symptoms were observed more often in SBBO-positive than SBBO-negative patients (64% vs 15%; P = .018).6Zhao J. et al.Neurogastroenterol Motil. 2014; 26: 794-802Crossref PubMed Scopus (50) Google Scholar In particular, patients with IBS with diarrhea and SBBO frequently reported improvement in abdominal symptoms including stool frequency and consistency.6Zhao J. et al.Neurogastroenterol Motil. 2014; 26: 794-802Crossref PubMed Scopus (50) Google Scholar Taken together, as argued by Sellin7Sellin J.H. Clin Gastroenterol Hepatol. 2016; 14: 209-211Abstract Full Text Full Text PDF PubMed Scopus (10) Google Scholar in his editorial, these findings suggest that lactulose HBT with concurrent scintigraphy provides an accurate diagnostic test for SBBO. If this is not available routinely for reasons of cost, then patients with abnormal results from glucose or lactulose HBT should be considered for a confirmatory test with concurrent scintigraphy to distinguish SBBO from rapid transit accompanied by early colonic fermentation. The use of serial tests (ie, HBT followed by scintigraphy) may be less ideal because of relatively high day-to-day variation in orocecal transit time. Looking ahead, the results of the combined lactulose HBT with concurrent scintigraphy investigation may help to identify the causes of IBS symptoms and to direct antibiotic therapy to patients that are likely to benefit. This would be welcome because the number needed to treat was >10 in unselected patients with IBS given rifaximin in the TARGET study.8Pimentel M. et al.Dig Dis Sci. 2011; 56: 2067-2072Crossref PubMed Scopus (76) Google Scholar If the outcome data of Zhao et al were confirmed, the proposed approach could reduce this to a number needed to treat of ∼3–4 and, at the same time, reduce the unnecessary and ineffective use of antibiotics in patients with IBS without SBBO. Scintigraphy Demonstrates High Rate of False-positive Results From Glucose Breath Tests for Small Bowel Bacterial OvergrowthClinical Gastroenterology and HepatologyVol. 14Issue 2PreviewBreath tests for hydrogen and/or methane are used to detect small bowel bacterial overgrowth (SBBO), but false-positive results can arise from clinical conditions that accelerate small bowel transit and deliver unabsorbed glucose to the colon. We investigated the prevalence of false-positive results from glucose breath tests by also evaluating patients with scintigraphy. Full-Text PDF ReplyClinical Gastroenterology and HepatologyVol. 14Issue 10PreviewThe comments by Deng et al on recent literature point out the necessity of using concurrent scintigraphic assessment of orocecal transit time when attempting to attribute increases in breath hydrogen or methane levels after lactulose ingestion to small-bowel bacterial overgrowth. We agree, but want to emphasize the importance of the scintigraphy protocol used to avoid a false diagnosis of bacterial overgrowth. In the studies cited by Deng et al, the goal was to distinguish, from among groups of patients with putative irritable bowel syndrome or lactase deficiency, patients whose symptoms might result from bacterial overgrowth. Full-Text PDF
Active Ageing —Another Way to Oppress Marginalized and Disadvantaged Elders?

R. Ranzijn

DOI: https://doi.org/10.1177/1359105310368181

2010-07-01

Journal of Health Psychology

Abstract:This article questions whether the concept of active ageing unintentionally devalues the life experiences of disadvantaged groups of older people. It is argued that talking up the expectation that older people will continue to be physically active may further marginalize significant groups of elders, including those from diverse non-dominant cultural groups. The article draws on a study of Australian Aboriginal Elders to illustrate this point, with suggestions about culturally appropriate ageing policies. The article concludes that alternative conceptions of ageing, such as ‘ageing well’ or ‘authentic ageing’, may better capture the cultural diversity of ageing and promote social inclusion.
The Dietary Features of Diarrhea Predominant Irritable Bowel Syndrome Patients with Small Intestinal Bowel Overgrowth

H Wei,Z J Liu,K Wang,W Zheng,L P Duan

DOI: https://doi.org/10.3760/cma.j.issn.0578-1426.2017.08.003

2017-01-01

Abstract:Objective: To explore the diet features of diarrhea predominant irritable bowel syndrome (IBS-D) with small intestinal bacterial overgrowth (SIBO). Methods: IBS-D patients were enrolled in outpatient department of Peking University Third Hospital from March 2015 to April 2016. Healthy volunteers were recruited as controls (HC). All the subjects completed screening examinations, clinical and food investigation, and lactulose methane and hydrogen breath test (LMHBT). The high fat diet is defined as the daily total calories supplying from fat is more than 50%. Results: Eighty-eight IBS-D patients and 32 HC were finally enrolled. The positive rate of LMHBT in IBS-D was significantly higher than that of HC[39.8% (35/88) vs 12.5%(4/28), P=0.005]. The 28 HC with negative LMHBT were enrolled in the follow-up analysis. (1) The BMI of IBS-P (IBS-D with positive LMHBT) was significantly lower than IBS-N (IBS-D with negative LMHBT) [(21.57±0.54) vs (23.30±0.53)kg/m(2,) P=0.032]. IBS-D patients with SIBO had higher scores of abdominal pain assess. (2) The proportion of dietary protein and carbohydrate in IBS-D was significantly higher than that of HC (14.39% vs 12.22%, P=0.001; 53.94% vs 46.25%, P=0.003, respectively). The proportion of diet fat was significantly higher in IBS-P than IBS-N[(47.19±2.62)% vs (40.74±1.66)%, P=0.038]. (3) The baseline of breath methane in IBS-P was significantly higher than that of in IBS-N[(8.69±0.39) ×10(-6) vs (6.39±0.47) ×10(-6,) P=0.002]. IBS-D patients with high fat diet had higher LMHBT positive rate than that of non-high fat diet patients[54.2% (13/24) vs 17.2% (11/64), P=0.001]. Breath methane peak value was positively correlated with the fat proportion of diet (r=0.413, P=0.022). Conclusions: About 39.8% IBS-D patients diagnosed by Rome Ⅲ are combined with SIBO. SIBO may affect IBS-D patients' nutritional status. High fat diet might be one of the risk factors for IBS-D with SIBO. Proper diet structure might reduce the prevalence of IBS-D, especially for IBS-D with SIBO.
Treatment of small intestinal bacterial overgrowth: Conventional antibiotic therapy and alternative therapy - probiotics and low FODMAP diet

Maria Litwiniuk,Marcin Zaniuk,Kamil Hurkała,Dominika Antonik,Barbara Denys,Karolina Góra,Wojciech Zdziennicki,Patryk Zimnicki,Marta Lato,Konrad Iberszer

DOI: https://doi.org/10.12775/jehs.2023.41.01.005

2023-06-27

Abstract:Introduction and purpose of the study: Small intestinal bacterial overgrowth syndrome (SIBO) is a syndrome characterized by an increased number of bacteria in the small intestine. The condition causes many non-specific symptoms such as diarrhea, abdominal pain and bloating. The purpose of this study is to review the current knowledge regarding treatment options for SIBO. Methodology: A literature review was conducted based on PubMed, GoogleScholar databases and American College of Gastroenterology (ACG) guidelines. Current knowledge: SIBO is a heterogeneous syndrome. Symptoms of bacterial overgrowth include bloating, abdominal pain and abnormal bowel motility. In more severe cases, patients may experience malabsorption leading to weight loss and malnutrition. SIBO can occur in healthy individuals, but very often accompanies other conditions. The primary test for diagnosis is non-invasive lactulose or glucose breath tests. For treatment, the antibiotic rifaximin is preferred. It exhibits a broad spectrum of activity and a low toxicity profile. Treatment may also include diet therapy and the use of probiotics. Summary: SIBO continues to be both a diagnostic and therapeutic problem. Effective treatment includes not only elimination of the bacteria but also treatment of predisposing conditions. Conclusions of the study show a positive effect of rifaximin on the reduction of SIBO symptoms and improvement of patients' quality of life. The use of certain probiotics has a proven effect. According to the currently available literature, the effectiveness of the low-FODMAP diet in SIBO is hypothetical and further studies are needed to unequivocally confirm its efficacy.
Small Intestinal Bacterial Overgrowth and Low-Grade Systemic Inflammation in 50 Patients with Irritable Bowel Syndrome

Chen Jian,Qiu Zhibing,Luo Zhongguang,Zhang Huilu,Liu Jie

DOI: https://doi.org/10.3760/cma.j.issn.0254-1432.2018.11.009

2018-01-01

Abstract:Objective To investigate the incidence of small intestinal bacterial overgrowth (SIBO) and systemic low-grade inflammation in patients with irritable bowel syndrome (IBS ) .Methods From June to October in 2017 ,50 cases of IBS patients who met Rome Ⅳ criteria were consecutively collected at Outpatient Department of Gastroenterology of Shanghai Huashan Hospital .The incidence of SIBO was detected by hydrogen lactulose breath test (LBT) and methane LBT .The incidence of systemic low-grade inflammation in IBS patients was determined by fractional exhaled nitric oxide (FeNO) breath test .Chi-square test was used for statistical analysis .Results Among 50 IBS patients ,the positive rate of FeNO was 70％ (35/50) ,and the number of FeNO positive cases in diarrhea-predominant (n=28) ,constipation-predominant (n= 14) and mix-type (n= 8) IBS paitents was 18 ,11 and six ,respectively ,and the difference was not statistically significant among three groups (χ2=1 .020 ,P=0 .600) .The incidence rate of SIBO was 60％ (30/50) ,with 20 cases (40％ ) being only positive for hydrogen LBT ,seven cases (14％ ) being methane LBT ,and three cases (6％ ) being both positive .The numbers of hydrogen LBT and methane LBT in diarrhea-predominant ,constipation-predominant ,and mix-type IBS patents were 17 , three ,three and two ,six ,two ,respectively .There were statistically significant differences in positive rates of hydrogen LBT and methane LBT among three groups (χ2 =6 .076 and 6 .392 ,both P<0 .05) . The positive rate of FeNO in IBS patients with SIBO was higher than that of IBS patients without SIBO (90％ ,27/30 vs .40％ ,8/20) ,and the difference was statistically significant (χ2 =14 .286 ,P<0 .01) . Conclusions Combination of hydrogen LBT and methane LBT has a higher detection rate of SIBO than traditional single hydrogen LBT . There is a correlation between SIBO and systemic low-grade inflammation in IBS patients .
The prevalence of small intestine bacterial overgrowth in irritable bowel syndrome is much higher with lactulose than glucose breath test: results of a retrospective monocentric study.

François Mion,Fabien Subtil,Christelle Machon,Sabine Roman,Anne Mialon

DOI: https://doi.org/10.1016/j.clinre.2024.102482

IF: 3.189

2024-10-20

Clinics and Research in Hepatology and Gastroenterology

Abstract:Background Glucose (GBT) and lactulose (LBT) breath tests have been recommended for the diagnosis of small intestinal bacterial overgrowth (SIBO). LBT may yield a higher prevalence of SIBO diagnosis, because of its limited small bowel absorption, and therefore colonic fermentation. The aim of this retrospective study was to confirm this hypothesis, in irritable bowel syndrome patients (IBS). Methods Among a cohort of 995 patients who underwent GBT or LBT, 287 with typical IBS according to Rome IV criteria, without past digestive surgery or significant medical comorbidities, were included. Results 155 IBS patients underwent GBT, and 132 LBT (71% women, mean age 45±15, mean BMI: 22.6±4.3 kg/m 2 ). There were no difference between both groups in terms of demographics, IBS type and severity of symptoms. The prevalence of SIBO according to LBT was 47%, versus 4.5% only with GBT (p<0.001). The prevalence of methane values ≥ 10 ppm were similar in both groups (34%). Conclusion LBT is very frequently positive in IBS patients, as compared to GBT. The 2 tests are thus not interchangeable for the diagnosis of SIBO. Furthermore, the positivity of both tests was not correlated with symptoms, which may indicate a poor clinical interest of these tests in IBS.

gastroenterology & hepatology
Intestinal Microecology and Quality of Life in Irritable Bowel Syndrome Patients

Jian-Min Si,Ying-Cong Yu,Yu-Jing Fan,Shu-Jie Chen

DOI: https://doi.org/10.3748/wjg.v10.i12.1802

IF: 5.374

2004-01-01

World Journal of Gastroenterology

Abstract:AIM: It has been noticed that gastroenteritis or dysentery plays a role in pathogenesis of irritable bowel syndrome (IBS), and antibiotics can increase functional abdominal symptoms, both of which may be partly due to intestinal flora disorders. This study was to determine the change of gut flora of IBS, a cluster of abdominal symptoms. Because of the chronic course and frequent occurrence of the disease, IBS patients suffered much from it. So the quality of life (Qol) of IBS patients was also evaluated in this study.METHODS: Twenty-five Rome II criteria-positive IBS patients were recruited, and 25 age and gender-matched healthy volunteers were accepted as control. The fecal flora, including Lactobacillus, Bifidobacterium, Bacteroides, C. perfringens Enterobacteriacea and Enterococus, were analyzed quantitatively and qualitatively. We also calculated the ratio of Bifidobacterium to Enterobacteriaceae (B/E ratio) in both IBS patients and controls. In both groups, the data were further analyzed based on age difference, and comparisons were made between the younger and elder subgroups. We also evaluated the quality of life (QoL) of IBS patients and the control group using the Chinese version of SF-36 health questionnaire.RESULTS: In IBS patients, the number of fecal Bifidobacterium was significantly decreased and that of Enterobacteriaceae was significantly increased compared with that in healthy controls (both P<0.05). The mean microbial colonization resistance (CR) of the bowel in IBS patients was smaller than 1, making a significant difference compared with that in control which was more than 1 (P<0.01). There was no significant difference in gut flora between two subgroups. While in control, the elder subgroup presented more Enterobacteriacea than the younger one (P<0.05). Compared with the control group, IBS patients had significantly lower scores on all SF-36 scales, with the exception of physical functioning. However, there was no significant correlation between quality of life and enteric symptoms in IBS patients.CONCLUSION: There are intestinal flora disorders in IBS patients, which may be involved in triggering the IBS-like symptoms. IBS patients experience significant impairment in QoL, however, the impairment is not caused directly by enteric symptoms.
CD56‐positive (nasal‐type T/NK cell) lymphoma arising on the skin

Shin-Ichi Ansai,K. Maeda,M. Yamakawa,M. Matsuda,Souichi Saitoh,Shinobu Suwa,H. Saitoh,M. Ohtsuka,K. Iwatsuki

DOI: https://doi.org/10.1111/j.1600-0560.1997.tb01320.x

1997-09-01

Journal of Cutaneous Pathology

Abstract:Several authors have reported cases of patients with malignant lymphoma with unique characteristics, designated nasal‐type T/NK cell lymphoma, which expresses the natural killer (NK) cell marker and shows frequent extra‐nodal involvement and poor prognosis. We report 2 cases of this type of lymphoma which were CD56‐positive and showed a histopathologically angiocentric pattern with cutaneous and subcutaneous tumorous lesions. Patient 1 had extensive invasion of skin, underlying skeletal muscle, spleen and bone marrow, and died of sepsis 34 months after onset. Patient 2 had multiple subcutaneous nodules and invasion to mammary gland, lung, lymph node and spleen at the time of her first visit. She died of a rapid invasion of lymphoma cells to the liver 5 months after onset. Both patients showed similar immunophenotypes of tumor cells (CD2+, CD3−, CD4−, CD8−, CD20−, CD56+) and germ line configuration of the heavy chain of immunoglobulin (JH), T‐cell receptor C beta‐1 subunit DNA and T‐cell receptor J gamma subunit DNA. Epstein‐Barr virus early regions RNA was demonstrated in the nuclei of tumor cells of both patients with in situ hybridization. The histopathological examination of the skin lesions of both patients revealed the features of angiocentric lymphoma. The detection of CD56 in the tumor cells of cutaneous lymphomas should be routinely performed for the early diagnosis of this type of lymphoma with extremely poor prognosis.
Small intestinal bacterial overgrowth and low-grade systemic inflammation in patients with inflammatory bowel disease

Yili Tong,Xiaofeng Yu,Yang Yu,Lin Mi,Ziyan Zhang,Zhijun Bao,Xiaofeng Yu

DOI: https://doi.org/10.19193/0393-6384_2021_5_454

2021-01-01

Acta medica mediterranea

Abstract:Background and Aim: To investigate the incidence of small intestinal bacterial overgrowth (SIBO) and low-grade systemic inflammation in patients with inflammatory bowel disease (IBD). Methods: From August 2018 to December 2019, 71 patients with inflammatory bowel disease were recruited, and 30 healthy people who came to our hospital for physical examinations at the same time were selected as the control group. The lactulose hydrogen breath test (LBT) and methane LBT were used to detect the prevalence of SIBO. The incidence of low-grade systemic inflammation in IBD patients was determined by the fractional exhaled nitric oxide (FeNO) breath test. The chi-squared test was used for statistical analysis. Results: The positive rate of SIBO in the IBD group was 33.8 %, which was significantly higher than that in the healthy control group (6.6 %) (P<0.01). The incidence of SIBO between UC and CD groups was not significantly different (P = 0.551). The SIBO positive rate was significantly increased in CD patients with no ileocecal valve, ileocecal valve malformation, or intestinal stenosis (P<0.05). The SIBO negative rate of IBD patients treated with infliximab (IFX) was significantly higher than that of IBD patients treated with 5-aminosalicylic acid (5-ASA) (P = 0.006). The FeNO positive rate in IBD patients with SIBO was higher (17/24) than that of IBD patients without SIBO (6/47), and the difference was statistically significant (P<0.01). Conclusion: SIBO in IBD patients was significantly higher than in healthy people, but there was no significant difference between UC and CD groups. The combination of the absence of the ileocecal valve, ileocecal valve malformation, and intestinal lumen stenosis was associated with CD combined with SIBO. IBD patients using IFX were less likely to incorporate SIBO than IBD patients using 5ASA. SIBO was associated with a low inflammatory response in IBD patients.
Continuous quality improvement and knowledge for improvement applied to asthma care.

L. Headrick,William Katcher,D. Neuhauser,E. McEachern

DOI: https://doi.org/10.1016/S1070-3241(16)30102-X

1994-10-01

The Joint Commission Journal on Quality Improvement

Abstract:

EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation.

Small Intestinal Bacterial Overgrowth in Patients with Irritable Bowel Syndrome: Clinical Characteristics, Psychological Factors, and Peripheral Cytokines

Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis

Clinical Value of Radionuclide Small Intestine Transit Time Measurement Combined with Lactulose Hydrogen Breath Test for the Diagnosis of Bacterial Overgrowth in Irritable Bowel Syndrome.

A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients.

Lactose intolerance in patients with chronic functional diarrhoea: the role of small intestinal bacterial overgrowth.

Prevalence and presentation of lactose intolerance and effects on dairy product intake in healthy subjects and patients with irritable bowel syndrome.

Prevalence of small intestinal bacterial overgrowth syndrome among patients with inflammatory bowel disease and its impact on nutritional status and clinical manifestations

Advances in Study on the Pathogenesis and Diagnosis of Small Intestinal Bacterial Overgrowth

Dietary Challenge Tests: Identifying Food Intolerance As a Cause of Symptoms in Irritable Bowel Syndrome Patients.

Tu2066 Prevalence of Irritable Bowel Syndrome in China: Joint Effects of Psychiatric Morbidity with Life Event Stress and Lactose Intake

Hydrogen Breath Testing with Measurement of Orocecal Transit for Diagnosis of Small Bowel Bacterial Overgrowth.

Active Ageing —Another Way to Oppress Marginalized and Disadvantaged Elders?

The Dietary Features of Diarrhea Predominant Irritable Bowel Syndrome Patients with Small Intestinal Bowel Overgrowth

Treatment of small intestinal bacterial overgrowth: Conventional antibiotic therapy and alternative therapy - probiotics and low FODMAP diet

Small Intestinal Bacterial Overgrowth and Low-Grade Systemic Inflammation in 50 Patients with Irritable Bowel Syndrome

The prevalence of small intestine bacterial overgrowth in irritable bowel syndrome is much higher with lactulose than glucose breath test: results of a retrospective monocentric study.

Intestinal Microecology and Quality of Life in Irritable Bowel Syndrome Patients

CD56‐positive (nasal‐type T/NK cell) lymphoma arising on the skin

Small intestinal bacterial overgrowth and low-grade systemic inflammation in patients with inflammatory bowel disease

Continuous quality improvement and knowledge for improvement applied to asthma care.